# TER-2013

Source: https://onco.cc/drugs/ter-2013/  
OnCo record `ter-2013` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TER-2013 is an experimental oral small-molecule inhibitor from Terremoto Biosciences, in phase 1 trials for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer and ovarian cancer and other cancers.

## Summary

TER-2013 is an oral small-molecule inhibitor (AKT1-selective) from Terremoto Biosciences. An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors. Its furthest stage is phase 1, for HR-positive HER2-negative breast cancer with PIK3CA, AKT1 or PTEN alterations, endometrial cancer, ovarian cancer and cervical cancer. ClinicalTrials.gov registers it in one study linked below. Registry: NCT07109726 phase 1/2, recruiting (start 2025-09-23). Company pipeline says it is 'currently being evaluated in a Phase 1 clinical trial'. FDA Fast Track per company release dated 3 June 2026. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: TER-2013
- Modality: Oral small-molecule inhibitor (AKT1-selective)
- Mechanism: An oral small molecule designed to selectively inhibit AKT1 while sparing AKT2 and AKT3, aiming to avoid the AKT2-linked high blood sugar, and the rash and diarrhoea, seen with earlier pan-AKT inhibitors.

## Sources

- Terremoto Biosciences: terremotobio.com: https://terremotobio.com/pipeline/
- Terremoto Biosciences: terremotobio.com: https://terremotobio.com/pipeline/
- Terremoto Biosciences: terremotobio.com: https://terremotobio.com/press-release/terremoto-biosciences-granted-fda-fast-track-designation-for-ter-2013-an-akt1-selective-small-molecule-inhibitor-for-breast-cancer/
- Terremoto Biosciences: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07109726
- ClinicalTrials.gov: trials of TER-2013: https://clinicaltrials.gov/search?intr=TER-2013

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Squamous cell carcinoma of the lung](https://onco.cc/cancers/lung-squamous-cell-carcinoma/)
- targets: [AKT](https://onco.cc/targets/akt/)
- companies: [Terremoto Biosciences](https://onco.cc/companies/terremoto-biosciences/)
- trials: [A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations](https://onco.cc/trials/nct07109726/)

---
JSON: https://onco.cc/api/v1/entities/ter-2013.json